Bluebird bio Inc - Asset Resilience Ratio
Bluebird bio Inc (BLUE) has an Asset Resilience Ratio of 0.00% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Bluebird bio Inc (BLUE) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2011–2023)
This chart shows how Bluebird bio Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Bluebird bio Inc total assets.
Liquid Assets Composition Over Time
This chart breaks down Bluebird bio Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Bluebird bio Inc long-term investment intensity to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Bluebird bio Inc maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Bluebird bio Inc Industry Peers by Asset Resilience Ratio
Compare Bluebird bio Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Bluebird bio Inc (2011–2023)
The table below shows the annual Asset Resilience Ratio data for Bluebird bio Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | $0.00 | $619.16 Million | -- |
| 2022-12-31 | 12.13% | $67.32 Million | $554.90 Million | -11.17pp |
| 2021-12-31 | 23.30% | $138.34 Million | $593.79 Million | -23.50pp |
| 2020-12-31 | 46.80% | $833.55 Million | $1.78 Billion | +1.69pp |
| 2019-12-31 | 45.11% | $779.25 Million | $1.73 Billion | +1.29pp |
| 2018-12-31 | 43.82% | $982.73 Million | $2.24 Billion | +15.85pp |
| 2017-12-31 | 27.97% | $531.60 Million | $1.90 Billion | -10.08pp |
| 2016-12-31 | 38.05% | $425.49 Million | $1.12 Billion | +2.77pp |
| 2015-12-31 | 35.29% | $353.68 Million | $1.00 Billion | +12.71pp |
| 2014-12-31 | 22.58% | $125.71 Million | $556.74 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $224.39 Million | -- |
| 2011-12-31 | 11.34% | $3.51 Million | $30.92 Million | -- |
About Bluebird bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disea… Read more